DOVER, DE / ACCESSWIRE / July 11, 2023 / Rexis Biotech Inc. ("REXIS") is delighted to announce its continued growth and expansion into new markets through its latest strategic partnership with 3Chi, Inc.. Rexis will supply and manufacture several ingredients and finished consumer goods such as ready to drink beverages. These beverages will be sold into the Rexis national distribution network with contracted distribution value of $24,600,000 divided over the next 3 years.
3Chi is the world's largest hemp derived, consumer packaged goods manufacturer and retailer; with national distribution into more than 35,000 retailers. 3Chi focuses on helping as many people as possible become the happiest and healthiest versions of themselves by giving them access to highly consistent cannabis products that did not previously exist.
Justin Journay, 3Chi CEO, stated, "We are extremely excited to announce our long term strategic partnership with Rexis. Rexis separates itself from the competition with their technology. Their Fused Polymorph Nano Fiber is several steps above of anything else that's in the marketplace right now. The quality of product that we have gotten from them is unsurpassed."
Keith Bushfield, Rexis CEO, Stated "This massive expansion of our strategic partnership with 3Chi combined with our Squared and Twist beverage brands makes Rexis undeniably the worlds largest hemp derived beverage manufacturer and distributor. Over the next 2 weeks, Rexis will begin delivering the first 1.7 million cans to our distribution and retail partners across the United States. This partnership also provides the perfect opportunity to announce the Rexis Biotech Inc. crowdfunding equity raise and corporate awareness campaign with WeFunder (www.wefunder.com/rexis). This crowdfunding campaign brings awareness to the Rexis platform while further building partner brand awareness."
On Behalf of the Board of Directors of
Rexis Biotech Inc.
Keith Bushfield
CEO/President
Rexis Biotech Inc.
Tel: (403) 606-1498
Email: [email protected]
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
About Rexis Biotech Inc.
Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams.
For more information, please visit: www.rexissystems.com
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE: REXIS BIOTECH